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Medicine • Volume 93,A Case of Severe Chlorite Poisoning Successfully Treated
With Early Administration of Methylene Blue, RenalReplacement Therapy, and Red Blood Cell Transfusion
Case Report
Andrea Gebhardtova, MD, Peter Vavrinec, PhD, Diana Vavrincova-Yaghi, PhD,
Mark Seelen, MD, PhD, Anna Dobisova, MD, Zora Flassikova, MD, Andrea Cikova, MD,hDRobert H. Henning, MD, Pintermittent hemodialysis, MB = methylene blue, MetHb =
methemoglobin, NADPH = nicotinamide adenine dinucleotideAbstract: The case of a 55-year-old man who attempted suicide by
ingesting <100mL of 28% sodium chlorite solution is presented. On
arrival in the intensive care unit, the patient appeared cyanotic with
lowered consciousness and displayed anuria and chocolate brown
serum.
Initial laboratory tests revealed 40% of methemoglobin. The
formation of methemoglobin was effectively treated with methylene
blue (10% after 29 hours).
To remove the toxin, and because of the anuric acute renal
failure, the patient received renal replacement therapy. Despite these
therapeutic measures, the patient developed hemolytic anemia and
disseminated intravascular coagulation, which were treated with red
blood cell transfusion and intermittent hemodialysis. These interven-
tions led to the improvement of his condition and the patient
eventually fully recovered. Patient gave written informed consent.
This is the third known case of chlorite poisoning that has been
reported. Based upon this case, we suggest the management of
sodium chlorite poisoning to comprise the early administration of
methylene blue, in addition to renal replacement therapy and
transfusion of red blood cells.
(Medicine 93(9):e60)cute kidney injury, BUN = body urea
ous renal replacement therapy, CVVH =
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venovenous hemodiafiltration, DIC = disseminated intravascular
coagulation, G6PD = glucose-6-phosphate dehydrogenase, IHD =phosphate, RRT = renal replacement therapy.
INTRODUCTION
Ingestion of sodium chlorite leads to an intoxication charac-terized by methemoglobin (MetHb) formation, hemolysis,
and acute renal failure.1 To our best knowledge, very little data
is available regarding the pathophysiology and treatment of
sodium chlorite intoxication as only two cases have been
reported so far.1 Methylene blue (MB) is an effective antidote
to methemoglobinemia as it activates nicotinamide adenine
dinucleotide phosphate (NADPH)-MetHb reductase, following
its conversion to leukomethylene blue by glucose-6-phosphate
dehydrogenase (G6PD).3 Methemoglobinemia in chlorite
poisoning, however, has been described as resistant to MB
treatment.1 Here we report a case of a patient with sodium
chlorite poisoning in which the associated severe methemo-
globinemia was successfully treated with MB, resulting in a
substantial decrease in MetHb formation. Nevertheless, the
successful lowering of methemoglobinemia did not preclude
the development of acute renal failure, which was effectively
treated by renal replacement therapy (RRT).
CASE
Day 1
A 55-year-old man was admitted to our intensive care
unit on May 23, 2011 after a suicide attempt. He had
ingested about 100mL of 28% sodium chlorite solution,
0.75 L of whiskey, and ibuprofen (12 tablets of 400mg),
after which he had attempted to hang himself.
His relatives found him lying on the floor, cyanotic, and
with lowered consciousness, as judged by his inadequate
response to verbal stimulus. Upon arrival of the ambulance,
he vomited and was immediately transported to the hospital’s
emergency department and subsequently admitted to our
department.
On arrival, his Glasgow Coma Scale score was 13
(E4M5V4), body temperature 33.6°C, heart rate 110/min,
lood pressure 150/80mm Hg, respiratory rate 28/min, pulse
ximetry (SpaO2) 65%. Physical examination revealed gene-
alized skin cyanosis, neck markings after strangulation, a
www.md-journal.com | 1
Twenty hours after admission, a norepinephrine dripsilent abdomen, and incontinence for urine and feces. Blood
samples from the arterial line rendered chocolate-brown serum.
Further physical examination showed no abnormalities.
The patient’s clinical history disclosed depression, a
previous suicide attempt, and alcohol abuse. He did not take
any regular medication. The patient was sedated, intubated,
and mechanically ventilated (ventilator Savina, Dr€ager Medi-
cal GmbH, Lu¨beck, Germany; ventilation mode was bilevel
positive airway pressure).
The initial laboratory evaluation showed the following:
hemoglobin 179 g/L, erythrocytes 5.45 1012/L, hematocrit
0.54, leukocytes 28.5 109/L, platelet count 279 109/L,
body urea nitrogen (BUN) 5.5mg/dL (Figure 1), creatinine
142 μmol/L (Figure 2), potassium 7.5mM, osmolality
351mosm/L, arterial lactate 6.5mM, and myoglobin
433 ng/mL. Bilirubin was elevated to 28mM whereas liver
enzymes and coagulation factors were normal.
Arterial blood gas analysis was performed while venti-
lated with 100% oxygen. The pH was 7.25, PaCO2 4.45 kPa,
PaO2 52.45 kPa, BE 12.2mmol/L, HCO3 14.1mmol/L,
SaO2 99%, and lactate 6, 48mmol/L. The laboratory tests
also revealed 40.1% of MetHb (Figure 3).
Toxicology revealed 2mg/g of alcohol in blood, ibuprofen
was found both in gastric content and urine. Gastric fibroscopy
was performed to check for burns in the gastrointestinal tract
caused by sodium chlorite. Multiple superficial necrotic spots
were found in the antrum, the body of the stomach, and the
duodenum, whereas edema of the pylorus was observed. After
3 days, ulcerations were found in the upper part of esophagus,
stomach, and duodenum.
On admission, the electrocardiogram showed peaked T
waves. A chest x-ray and a CT scan of the brain were normal.
Antidote therapy with MB was instituted 2 hours after
admission by an intravenous bolus of 34mg MB (approximate-
ly 0.5mg/kg, Bleu Patente V sodique Guerbet 2.5%, Guerbet,
Roissy CdG Cedex, France). Four and half hours after
admission, because of acute renal failure (anuria, hyperkale-
mia, metabolic acidosis), continuous venovenous hemodiafil-
Gebhardtova et altration (CVVHDF) was initiated on the multiFiltrate (Fresenius
Medical Care, Bad Homburg, Germany) with hemofilter














FIGURE 1. Plasma level of BUN over time of hospitalization. BUN¼b
2 | www.md-journal.comCare AG & Co. KGaA, Bad Homburg, Germany), with a blood
flow of 250mL/min, a hemodialysis flow of 1800mL/h, and a
substitution hemofiltration solution flow of 35mL/kg/h for a
total duration of 10.5 hours. Later that day, another 4 hours of
hemodialysis was performed because of hyperkalemia (Frese-
nius Medical Care 4008B; dialysis filter, FX80, Fresenius
Helixone, High-flux [Fresenius Medical Care AG & Co.
KGaA, Bad Homburg, Germany]).
After 14 hours, the lactate level dropped to 2.55mmol/L
whereas the level of MethHb decreased to 15.2%, further
declining to 10.2% after 29 hours (Figure 3). Within 24 hours,
the patient developed hemolytic anemia and disseminated
intravascular coagulation (DIC, hemoglobin levels dropped
from 179 to 116 g/L, thrombocytes from 279 to 164, D-dimer
29.1mg/mL, international normalized ratio: 1.8, activated
partial thromboplastin time ratio: 1.4). Over the course of the
next 4 days, the hemolytic anemia deteriorated. Hemoglobin
levels on the fifth day dropped to 59 g/L and platelet count to
77 109/L. In response, 4 units of packed red blood cells were
transfused in 3 hours, amounting in total to 1074mL).
Medicine • Volume 93, Number 9, August 2014was instituted (0.16 μg/kg/min) because of hypotension
(80/60mm Hg) during the next 37 hours.
Clinical Course >24 Hours
On day 8, the patient developed bronchopneumonia and
sepsis (body temperature 39°C, antibiotics were initiated).
On day 10, the gastric and esophageal ulceration
appeared improved, and on day 13 the patient was weaned
from mechanical ventilation. Day 17 onward, intermittent
hemodialysis (IHD) was performed every second day. By
day 22, the patient started to urinate (2500mL of urine/24 h,
with blood urea 12mg/dL (Figure 1), creatinine 428 μmol/L
(Figure 2), and an estimated GFR of 15.6mL/min). He was
subsequently transferred to a medium care facility without
further need of hemodialysis. In total, hemodialysis had been
performed 16 times during hospitalization.By day 43, the patient was transferred to a psychiatric
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Here we report a case of a patient poisoned by sodium
chlorite in a suicide attempt, who then developed methemo-
globinemia, hemolysis, and acute renal failure.
The patient ingested <100mL of 28% sodium chlorite,
which led to a 40% rise in MetHb level. He was treated with
MB, which decreased MetHb levels to about 10% within
24 hours. The lowering of MetHb, however, proved insuf-
ficient to prevent development of subsequent hemolysis and
acute renal failure.
To our knowledge, only two prior cases of acute sodium
FIGURE 2. Plasma level of creatinine over time of hospitalization.chlorite intoxication have been reported in medical literature
previously. In the first case (Lin and Lim1), a patient was
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FIGURE 3. Plasma level of MetHb (%) over time of
hospitalization. Note that there are clearly 2 kinetics of MetHb
elimination: one that occurred within 24 hours with a half-life
of about 15 hours (MB administration, RRT) and second with a
half-life of about 65 hours (ordinary body elimination
mechanisms). CVVHDF¼ continuous venovenous
hemodiafiltration, MetHb¼methemoglobin.
ã 2014 Lippincott Williams & Wilkinsadministration of multiple doses of MB. MB in this case had
no effect on MetHb formation (MetHb about 50%). In the
second case (Romanovsky et al,2 MetHb about 10%), the
patient was treated with IHD, continuous venovenous
hemofiltration (CVVH), and red blood cell exchange. In both
cases, the patients developed hemolysis, DIC, and acute renal
failure that required IHD for renal recovery, and both
patients survived. Our patient (MetHb about 40%) was
treated with early administration of MB CVVHDF, followed
aysmethemoglobinemia by MB did not prevent the development
of acute renal failure.
Mechanism of MetHb Formation
MetHb formation after chlorite poisoning is due to
oxidation,5 causing the change of the iron ion of hemoglobin
from the ferrous state (Fe2+) to the ferric state (Fe3+) leading to
the loss of the ability of hemoglobin to bind oxygen.4 In the
physiological condition, the low level of MetHb (1%–3%) is
sustained by 2 important mechanisms. The first is the hexose-
monophosphate shunt pathway in the erythrocyte in which the
oxidizing agents are reduced by glutathione. The second, and
more important, mechanism preventing MetHb formation are 2
enzyme systems, diaphorase I and diaphorase II. These
2 enzyme systems require nicotinamide adenine dinucleotide
(NADH) and NADPH and reduce the ferric iron ion into its
original ferrous state, thus, turning MetHb into hemoglobin.
Chlorite-Induced Methemoglobinemia
Oxidative agents are capable of heme iron oxidation,
and thus cause MetHb formation. In 1964, chlorite ingestion
was associated with MetHb formation for the first time.6
When MetHb concentration is increased, tissue hypoxia
may occur, giving rise to symptoms including cyanosis,
shortness of breath, exercise intolerance, fatigue, dizziness, and
loss of consciousness. Severe methemoglobinemia (>50%)
causes dysrhythmias, seizures, and coma, whereas death is
imminent when MetHb levels exceed >70%. Arterial blood
with elevated MetHb appears with a characteristic chocolate-
brown color.
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Based on our and the previous 2 reported cases, it
seems that MetHb formation is dependent on the amount of
chlorite ingested. In the case of Lin and Lim,1 the patient
who was presented with >50% MetHb had ingested a teacup
of 10% chlorite, whereas in the second case (Romanovsky
et al2), MetHb was around 6% in a patient who had ingested
a mouthful of 28% chlorite diluted with water in a cup. Our
patient had ingested <100mL of 28% chlorite, rendering a
MetHb level of 40%. This suggests that oxidation of
Gebhardtova et alhemoglobin by chlorite is dose-dependent, and even a
before the occurrence of hemolysis. Therefore, pending finiterelatively small amount of chlorite, as in the case of
Romanovsky et al,2 can cause MetHb formation.
The Effectiveness of MB
To date, no standard treatment procedures for chlorite
poisoning have been established, due to the lack of reported
cases. Because of the chemical similarity, chlorite (ClO2 )
poisoning resembles chlorate (ClO3 ) poisoning. However,
chlorate is far more common in households than chlorite,
hence poisoning with chlorate is much better documented.
Chlorate poisoning displays similar symptoms, that is,
oxidative damage to red blood cells and kidney, and also
causes methemoglobinemia followed by hemolysis and
anuric acute renal failure.7
MB counteracts methemoglobinemia in 2 ways. First, MB
is reduced to leukomethylene blue by the erythrocyte’s MetHb
reductase in the presence of NADPH, which subsequently
reduces MetHb to hemoglobin. Additionally, MB activates
diaphorase II up to 5 times its normal level.3
MB is commonly used in the treatment of methemo-
globinemia.3 Nevertheless, the effectiveness of MB in the
treatment of methemoglobinemia caused by chlorite (or chlorate)
poisoning is debated. Some authors found MB to be effective
while others not. MB is reported to be ineffective in many cases
of chlorate poisoning. Steffen and Seitz7 reported a case of
unsuccessful use of MB in chlorate poisoning and Singelmann
et al8 further showed by experiments on erythrocytes that
chlorate denatures the G6PD, possibly explaining the ineffec-
tiveness of MB. However, Lee et al9 successfully used MB in
their case of chlorate poisoning. The lack of effectiveness of
MB in chlorite/chlorate poisoning is attributed to the denatur-
ation of the erythrocyte G6PD by sodium chlorite (or chlorate).10
Consequently, MB-induced conversion of MetHb back to hemo-
globin fails, because its action is dependent on nicotinamide-
adenine dinucleotide phosphate (NADP+) produced by G6PD,
as outlined above. Importantly, MB is ineffective in patients
with an inherited deficiency of G6DH, as it was assumed in the
case reported by Romanovsky et al.2 Therefore, special caution
needs to be taken with these patients. Exchange transfusion may
play a role in the management of severe hemolysis or in G6DH
deficiency associated with chlorite-induced methemoglobinemia
in which MB is rather contraindicated.
A failure of MB to reverse MetHb may perhaps
originate from a concentration of chlorite, the longer expo-
sure needed for G6PD denaturation, and even from an
individual variability in the sensitivity of G6PD dehydro-
genase to oxidants. Lee et al,9 who successfully used MB in
chlorate poisoning, postulates that a “window of opportunity”
exists when MB is used within 6 hours after ingestion of
chlorate, prior to hemolysis. Indeed, in our case, MB was
used within this period (2 hours after admission—before
institution of hemolysis). Therefore, the early use of MB
seems to be essential in its therapeutic effect.
4 | www.md-journal.comUnfortunately, we did not assess denaturation of G6PD
in the erythrocytes, so we cannot exclude its presence at the
time of MB administration.
Furthermore, MB is more effective in normal erythrocytes
as opposed to ruptured erythrocytes. It is likely that both of the
patients reported by Lee et al9 and by us received MB prior to
hemolysis. In the presence of hemolysis, high-dose MB (20–
30mg/kg) can even induce MetHb formation.9 Ascorbic acid,
N-acetylcysteine and tocopherol may be used as an alternative
to MB, but these treatments currently lack proof of efficacy.
While no experimental studies in man have been con-
ducted, experience from the clinics show that MB increases the
rate of MetHb conversion back to hemoglobin up to 6-fold.3
Improvement usually occurs within 30 minutes after MB
injection,9,11 which is in line with our observation of MetHb
level decreasing from 40.1% to 31.8% within 2 hours after MB
administration. Despite this lowering, it is however difficult to
provide a conclusive statement on whether MB lowered MetHb
in the presented case. The decline in MetHb we observed
appears very modest compared with the one reported in a case
of chlorate poisoning by Lee at al,9 in which MetHb level
dropped from 66.8% to <1% within 4 hours after MB. Except
for the different poisoning agents, that is, chlorite versus
chlorate, the difference in MB effect on MetHb may also
represent a dosing issue, as we employed 0.5mg/kg MB,
whereas Lee et al9 used 2mg/kg. Alternatively, the poisoning
with chlorite in our case might have (already) caused partial
inactivation of G6PD, leading to a slower rate of MetHb
reduction by MB. The considerable time lag between ingestion
of chlorite and hospitalization in our patient would then
emphasize the importance of early MB administration.
Remarkably, the decrease in MetHb seemed to follow a
2-phase kinetic profile. The rapid decline, lasting about
30 hours, seems related to the administration of MB. Such
notion is supported by MB having a half-life of about
6 hours, which would render the drug ineffective after about
a day. The second phase, showing a 4-fold lower elimination
rate, is caused by spontaneous decrease.
Importantly, MB infusion does not seem to cause negative
effects in patient with chlorite poisoning when administered
Medicine • Volume 93, Number 9, August 2014data, our recommendation would be to institute MB treatment
prior to hemolysis, up to 6 hours past ingestion.
Acute Kidney Injury
In this case and other 2 cases, the reduction of methemo-
globinemia did not prevent the development of acute kidney
injury (AKI). Because of the different levels of methemo-
globinemia in these cases, the development of AKI seems
unrelated to methemoglobinemia. Indeed, AKI is not a common
consequence of methemoglobinemia. More likely, AKI develops
independently of methemoglobinemia in response to the direct
toxic effect of chlorite on renal tissue. Lin and Lim1 reported
renal tubulointerstitial changes with interstitial infiltration,
edema, and moderate damage of tubules, but no changes at the
glomerular level in biopsy of the chlorite poisoned patient.
Furthermore, chlorite ingestion in rats was reported by Hef-
fernan et al5 to cause increased kidney/body weight ratio.
Jackson et al12 reported that sodium chlorate acutely constricts
renal vessels that might lead to a decrease in renal blood flow
causing anuric acute renal failure. The chemical similarity
between chlorate and chlorite suggests that in our case the cause
of AKI might have been mediated via the same mechanism, that
ã 2014 Lippincott Williams & Wilkins
Medicine • Volume 93, Number 9, August 2014is, an acute toxic effect on renal tubules or arterioles. To reduce
chlorite toxicity, it is therefore advisable to remove chlorite from
circulation by early institution of RRT.
Renal Replacement Therapy
RRT can be applied intermittently, such as IHD or
continuous renal replacement therapy (CRRT), such as in
CVVHDF, which was used in our case. IHD achieves
removal of fluid, solutes, and toxins. Rapid fluid removal
during IHD has, however, been suggested to lead to
hypotension, with the potential for further renal injury
and prolongation of AKI.13 The kinetics of chlorite is
largely unknown. Thus, it is unknown, whether chlorite is
rapidly removed or inactivated, or is released back from
the tissues into the blood stream, thereby prolonging
exposure of tissues. IHD would be more effective in
chlorite removal if the rate of chlorite removal in plasma
was linear, that is, not influenced by its back-releasing
from tissues. If otherwise, then CRRT may be the better
choice because of its continuous and prolonged nature.
Thus, at present, it is unclear whether continuous RRT is
superior to IHD in preventing hemolysis and removing
chlorite from plasma. An additional benefit of continuous




12.balance in hemodynamically unstable critically ill patients,
as it was in our case.13
Effect of Chlorite on Hemolysis, DIC, and AKI
Our patient developed within 24 hours hemolysis and
DIC, which deteriorated in the course of the next 4 days. It
is of note that in the currently presented case as well as in 2
previously reported cases hemolysis, DIC, and AKI occurred.
As studies varied considerably with respect to the level of
MetHb, this observation suggests that the MetHb is not
causally related to the hemolysis in chlorite poisoning.
Rather, the hemolysis seems caused by a toxic action of the
chlorite per se, possibly related to its oxidative properties.
Moreover, to our knowledge, there is no data available in the
current literature demonstrating that MetHb causes or
precedes hemolysis.
However, Singelmann et al8 reported that in vitro
chlorate induces hemolysis due to membrane protein poly-
merization, thus increasing erythrocyte membrane rigidity,
denaturation of globin (the essential protein subunit of
hemoglobin), crosslinking of membrane proteins, and inacti-
vation of membrane enzymes causing the disruption of
erythrocytes membranes.
Such proposition seems in accord with the chain of
events typical for hemolytic anemia caused by oxidative
compounds in vivo, featuring denaturation of hemoglobin
and Heinz body hemolytic anemia.14
Similar to hemolysis, DIC may be directly related to the
oxidative properties of chlorite, as it is likely a consequence of
hemolysis because of the coagulating properties of the hemo-
lyzed erythrocyte “ghost cells”.15
Thus, most likely, the oxidative effect of chlorite, rather
than its induction of MetHb, induces the majority of symp-
toms, including hemolysis, DIC, and damage of renal tissue.
Finally, in the absence of severe methemoglobinemia,
we believe that the intermittent lactic acidosis resulted from
a combination of decreased oxygen-carrying capacity and
reduced tissue perfusion.
ã 2014 Lippincott Williams & WilkinsChlorate salts are common household chemicals used
for cleaning or as bleach because of their oxidative capabili-
ties. Chlorite salts are however less frequent in households,
but an aqueous solution of 28% sodium chlorite (NaClO2) in
distilled water is branded by the product name mineral
miraculous solution (http://jimhumble.org), which is used
orally as diluted solution. Our case report shows that chlorite
ingestion is life threatening, even in small amounts (Roma-
novsky et al2). Therefore, leaflets should warn consumers to
take special caution and measures, and thus avoid accidental
poisoning.
Taken together, our report fuels the notion that early
administration of MB, that is, before development of
hemolysis, exerts a beneficial effect in chlorite poisoning
because of a rapid decrease in MetHb levels, leading to
an improved oxygenation of tissues. In addition, the
management of sodium chlorite intoxication appears to
benefit from early institution of RRT to manage AKI and
to speed up clearance of chlorite. Finally, transfusion of
red blood cells is warranted to recover red blood cell
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